Clinical Trials Browser

Phase 1/2 × Not yet recruiting × Ipilimumab × Clear all

NCT06683755 2024-11-12

Phase I/IIa Dose Finding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in First Line Therapy of Metastatic Melanoma (TRINITY)

Phase 1/2 Not yet recruiting

Melanoma